The Neuralink PRIME (Precise Robotically Implanted Brain-Computer Interface) Study is a groundbreaking clinical trial by Neuralink Corp. designed to assess the safety and initial functionality of its brain-computer interface (BCI) technology. The study focuses on the N1 Implant, an intracortical BCI designed to record brain activity through 1,024 electrodes distributed across 64 flexible threads. These threads, thinner than human hair, are robotically implanted into the brain using the R1 Robot. The goal is to establish a wireless digital link between the brain and computers, potentially restoring autonomy to individuals with quadriplegia, spinal cord injuries, or amyotrophic lateral sclerosis (ALS) by enabling them to control external devices with their thoughts.
Neuralink, founded by Elon Musk, aims to create a generalized input/output platform interfacing with the human brain to solve various neurological ailments. The PRIME study is currently enrolling participants with quadriplegia (limited function in all four limbs) due to spinal cord injury or ALS who are at least 22 years old, at least one year post-injury, and have a consistent caregiver. Participants will be compensated for study-related costs, such as travel. While the devices used in the study are investigational and not for sale, estimates for the commercial procedure, including the implant, exams, and labor, are around $10,500, with potential costs to insurers reaching up to $50,000. Elon Musk has expressed the goal to reduce the price to approximately $2,000 to $3,000, similar to LASIK. Currently, the PRIME study is open at sites including Barrow Neurological Institute in Phoenix, Arizona, and the University of Miami Health System's Miami Project to Cure Paralysis.
